Informe anual 2023 y aviso de la AGM 2024
Zotefoams plc
(la 'Compañía' o el 'Grupo')
2023 Annual Report and Notice of the 2024 Annual General Meeting
19 April 2024 - The Company has published its 2023 Annual Report and the Notice of the 2024 Annual General Meeting to be held at 675 Mitcham Road, Croydon CR9 3AL on 22 May 2024 at 10.00 a.m. on:
https://www.zotefoams.com/investors/annual-interim-reports/
https://www.zotefoams.com/investors/agm/
In compliance with Listing Rule 9.6.1, the following documents will be submitted to the National Storage Mechanism and will shortly be available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
1. | Informe anual para el año terminado el 31 de diciembre de 2023 prepared using the single electronic reporting format specified in the TD ESEF Regulation, incorporating the Notice of the 2024 Annual General Meeting; and |
2. | Formulario de representación para la Junta General Anual de 2024. |
A condensed set of the financial statements, the Chair's introduction, the Group CEO's review and the Group CFO's review in respect of the Annual Report were included in the unaudited preliminary results announcement issued on 19 March 2024, which may be found at:
www.zotefoams.com/investors/announcements/
This announcement contains, in Annex A, additional information for the purposes of compliance with the Disclosure, Guidance and Transparency Rules, including the statement of Directors' responsibilities in respect of the financial statements, a description relating to principal risks and uncertainties, and details of related party transactions. This information is extracted from the 2023 Annual Report. This announcement is not a substitute for reading the full Annual Report. Page and note references in the text below refer to page numbers and notes in the 2023 Annual Report.
A presentation open to all existing and potential shareholders will be given after the AGM on 22 May 2024 at 11.30am on the Investor Meet Company platform:
https://www.investormeetcompany.com/zotefoams-plc/register-investor.
Los inversores que ya sigan a Zotefoams plc en la plataforma Investor Meet Company serán invitados automáticamente.
Consultas:
Lydia Harratt
Secretario de la empresa del grupo
Zotefoams plc
020 8664 1600
Acerca de Zotefoams plc
Zotefoams plc (LSE - ZTF) es un líder mundial en tecnología de materiales celulares que ofrece soluciones de materiales óptimas para el beneficio de la sociedad. Utilizando una variedad de procesos de fabricación únicos, incluida la expansión de nitrógeno respetuosa con el medio ambiente para AZOTE ligero® poliolefina y ZOTEK® espumas de alto rendimiento, Zotefoams vende a diversos mercados en todo el mundo. Zotefoams utiliza sus propios materiales celulares para fabricar T-FIT® Aislamiento avanzado para mercados industriales exigentes. Zotefoams también posee y licencia la tecnología patentada de espuma microcelular para reducir el uso de plástico en aplicaciones de extrusión y para ReZorce.® Embalaje barrera reciclable mono-material.
Zotefoams tiene su sede en Croydon, Reino Unido, con sitios de fabricación adicionales en Kentucky, EE. UU. y Brzeg, Polonia (fabricación de espuma), Oklahoma, EE. UU. (fabricación y conversión de productos de espuma), Massachusetts, EE. UU., Stilling, Dinamarca (tecnología de espuma microcelular) y Jiangsu. Provincia, China (T-FIT).
www.zotefoams.com
ÁZOE®, ZOTEK®, ReZorce® y T-FIT® son marcas comerciales registradas de Zotefoams plc.
anexo A
Declaración de responsabilidades de los directores con respecto a los estados financieros
The Directors consider the Annual Report, taken as a whole, to be fair, balanced and understandable.
Los Directores son responsables de preparar el Informe Anual y los estados financieros de acuerdo con la ley y la regulación aplicable.
Company law requires the Directors to prepare financial statements for each financial year. Under that law, the Directors have prepared the Group and Company financial statements in accordance with UK-adopted international accounting standards. Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and Company and of the profit or loss of the Group and Company for that period. In preparing the financial statements, the Directors are required to:
· | Seleccione políticas contables adecuadas y luego aplíquelas consistentemente |
· | State whether applicable UK-adopted international accounting standards have been followed subject to any material departures disclosed and explained in the financial statements |
· | Make judgements and accounting estimates that are reasonable and prudent and |
· | Preparar los estados financieros sobre la base de negocio en marcha a menos que sea inapropiado suponer que el Grupo y la Compañía continuarán en el negocio. |
Los Consejeros también son responsables de salvaguardar los activos del Grupo y la Compañía y, por lo tanto, de tomar las medidas razonables para la prevención y detección de fraudes y otras irregularidades.
Los Consejeros son responsables de mantener registros contables adecuados que sean suficientes para mostrar y explicar las transacciones del Grupo y de la Empresa y revelar con razonable precisión en cualquier momento la situación financiera del Grupo y de la Empresa y permitirles asegurar que los estados financieros y las declaraciones de los Consejeros El informe de remuneración cumple con la Ley de Sociedades de 2006.
Los Directores son responsables del mantenimiento y la integridad del sitio web de la Compañía. La legislación del Reino Unido que rige la preparación y divulgación de estados financieros puede diferir de la legislación de otras jurisdicciones.
The Directors consider that the Annual Report, taken as a whole, is fair, balanced and understandable and provides the information necessary for shareholders to assess the position and performance, business model and strategy of the Group and Company.
Each of the Directors, whose names and functions are listed on pages 78 and 79 of the Annual Report, confirm that, to the best of their knowledge:
· | The Consolidated and Company financial statements, which have been prepared in accordance with UK-adopted international accounting standards, give a true and fair view of the assets, liabilities, financial position and profit of the Group and Company and |
· | The Group CEO's review includes a fair review of the development and performance of the business and the position of the Group and Company. A description of the principal risks and uncertainties faced by the Group and the Company is provided on pages 48 to 56. |
Principales riesgos e incertidumbres
The Group is exposed to a wide range of risks in addition to those listed, and these are managed through the risk management framework shown on page 47. This framework enables us to monitor for any increase in likelihood or impact and ensure that we have the appropriate mitigations in place. The details of our principal risks and uncertainties and the key mitigating activities can be found on pages 48 to 56. We are disclosing those risks and uncertainties that we believe have the greatest impact in achieving our strategic objectives.
Zotefoams' risk profile will evolve as the business grows at its targeted pace, although we expect these principal risks and uncertainties to remain broadly consistent.
Transacciones con partes relacionadas
directiva
The Directors of the Company as at 31 December 2023 and their immediate relatives control approximately 1.3% (2022: 1.3%) of the voting shares of the Company. Details of Directors' pay and remuneration are given in the Directors' Remuneration report on pages 90 to 103. Executive Directors are considered to be the only key management personnel. Details of compensation paid to key management personnel are included in note 5.
Subsidiaries and joint venture
Details of the joint venture and subsidiaries of the Company are set out in notes 9 and 13. These companies are considered to be related parties.
The following material transactions were carried out with related parties:
2023 | 2022 | |
Sale of goods: subsidiaries of the Company | 4,434 | 3,875 |
Sale of services: subsidiaries of the Company | 2,598 | 2,537 |
Loans given (net of repayments): subsidiaries of the Company | (708) | (2,419) |
Interest income: subsidiaries of the Company | 1,302 | 657 |
Sale of goods: joint venture of the Company | 2,944 | 3,444 |
Sale of services: joint venture of the Company | 368 | 232 |
Total | 10,938 | 8,326 |
Balances between the Company and its active subsidiaries and joint venture are as follows:
Receivable from/ | Inversión en | ||||
2023 | 2022 | 2023 | 2022 | ||
Zotefoams Inc. | 12,669 |
13,163 | - | - | |
Azote Asia Limited | 1,000 | 1,304 | - | - | |
MuCell Extrusion LLC | 7,904 | 6,511 | - | - | |
Zotefoams International Limited | 15,487 | 16,370 | 30,822 | 30,822 | |
Zotefoams T-FIT Material Technology (Kunshan) Limited | 2,014 | 3,438 | - | - | |
Zotefoams Poland Sp. z.o.o. | 1,190 | 291 | - | - | |
Zotefoams France SAS | (73) | (59) | - | - | |
T-FIT Insulation Solutions India Private Limited | - | 75 | - | - |
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.